BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/29/2016 8:32:00 PM | Browse: 809 | Download: 671
Publication Name World Journal of Gastroenterology
Manuscript ID 26605
Country/Territory Lebanon
2016-04-19 09:57
Peer-Review Started
2016-04-19 17:03
To Make the First Decision
2016-05-27 14:57
Return for Revision
2016-05-28 14:01
2016-06-17 00:00
Second Decision
2016-06-28 09:06
Accepted by Journal Editor-in-Chief
2016-06-29 01:21
Accepted by Company Editor-in-Chief
2016-07-06 18:30
Articles in Press
2016-07-06 18:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-07-21 10:25
Publish the Manuscript Online
2016-07-29 20:32
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Use of rifaximin in gastrointestinal and liver diseases
Manuscript Source Invited Manuscript
All Author List Rani H Shayto, Rachel Abou Mrad and Ala I Sharara
Funding Agency and Grant Number
Corresponding Author Ala I Sharara, MD, FACG, AGAF, Professor, Head, Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Cairo Street, Beirut 11-0236, Lebanon. ala.sharara@aub.edu.lb
Key Words Irritable bowel syndrome; Inflammatory bowel disease; Hepatic encephalopathy; Bacterial overgrowth; Diverticular disease
Core Tip Rifaximin is a poorly absorbed oral antibiotic with highly favorable safety profile. Rifaximin is effective in the treatment of traveler’s diarrhea, functional bloating and irritable bowel syndrome, small bowel bacterial overgrowth and in the prevention of recurrent overt hepatic encephalopathy. There is emerging evidence for a possible beneficial effect of rifaximin in the treatment of other disorders including uncomplicated diverticular disease and in the prevention of recurrent diverticulitis. The use of rifaximin is associated with a low incidence of development of spontaneous bacterial mutants or drug resistance among extra-intestinal flora.
Publish Date 2016-07-29 20:32
Citation Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651
URL http://www.wjgnet.com/1007-9327/full/v22/i29/6638.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i29.6638
Full Article (PDF) WJG-22-6638.pdf
Full Article (Word) WJG-22-6638.doc
Manuscript File 26605-Review.docx
Answering Reviewers 26605-Answering reviewers.pdf
Audio Core Tip 26605-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 26605-Conflict-of-interest statement.pdf
Copyright License Agreement 26605-Copyright assignment.pdf
Peer-review Report 26605-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 26605-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 26605-Scientific misconduct check.pdf
Scientific Editor Work List 26605-Scientific editor work list.pdf